Labcorp has expanded its integration agreement with Epic to make its complete test catalog available through Aura, Epic's laboratory platform — closing a gap that previously forced ordering clinicians to work outside the EHR or rely on incomplete menu access. The deal places Labcorp alongside Quest Diagnostics and other reference lab vendors already embedded in Aura, consolidating major send-out ordering within the workflow most health system clinicians already live in.
The operational shift is real for lab directors at Epic-connected health systems: reference lab ordering that once required portal-hopping or manual requisitions can now run natively inside the EHR, with test selection, ordering logic, and results routing handled through a single interface. That reduces friction at the front end, but it also tightens Epic's grip on the ordering relationship — the platform becomes the layer between the clinician and the lab, not the lab itself.
The competitive question now is what Aura integration actually costs reference labs in margin and pricing visibility over time. Epic controls the interface, the data, and increasingly the default ordering behavior — and any lab not on the platform risks being invisible at the point of order.
The Takeaway: Full Aura presence is table stakes for national reference labs now — being off-platform is a volume risk, not a feature gap. Lab vendors negotiating future Epic terms should treat interface access as a commercial lever, not an IT project. The labs that will feel this most are regional independents who lack the scale to negotiate comparable visibility.
GMAP predicts molecular alterations in gliomas directly from histopathology images — no additional sequencing required. The multicentre validation and interpretability features make it a credible candidate for resource-constrained labs where turnaround on molecular profiling is a bottleneck.
Lung function testing embedded race-based corrections for decades before regulators moved to remove them — a pattern that applies directly to any diagnostic AI trained on historically biased reference ranges. Labs and AI vendors deploying algorithmic tools without auditing their reference population assumptions are carrying the same liability forward.
A Lancet comment argues that digitising 100,000+ H&E slides has created the conditions for general-purpose pathology foundation models — using glioma molecular signature prediction as the proof-of-concept case. The piece marks a shift from slide digitisation as an archival project to an AI-training infrastructure question.
Project Santa Fe Foundation's Clinical Lab 2.0 initiative is plugging Life Data Lab's Vivica LabReports into its care gap workflow — a modest but directionally consistent move toward labs generating actionable intelligence rather than just results. Deployment scope and timeline are unspecified.
Diagnostic Medicine Consortium and Virchow Medical are partnering on longitudinal, evidence-based cancer therapy offerings. No financial terms, workflow specifics, or deployment timeline disclosed — file under watch-and-wait.